Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: Role of NO

Hypertension Research

Volumn 37, Issue 8, 2014, Pages 716-723

  Asanuma, Hiroshi ^a,b   Sanada, Shoji ^c   Asakura, Masanori ^b   Asano, Yoshihiro ^c   Kim, Jiyoong ^b   Shinozaki, Yoshiro ^d   Mori, Hidezo ^d   Minamino, Tetsuo ^c   Takashima, Seiji ^c   Kitakaze, Masafumi ^b  

^a KYOTO PREFECTURAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

atrial natriuretic peptide; coronary blood flow; cyclic GMP levels; ischemic hearts; nitric oxide

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CYCLIC GMP; HS 142 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; CYCLIC AMP; NPPA PROTEIN, HUMAN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAGLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY REPERFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; FEMALE; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PERFUSION PRESSURE; TREATMENT RESPONSE; VENOUS BLOOD; ANIMAL; CORONARY BLOOD VESSEL; DOG; DRUG EFFECTS; HEART CONTRACTION; HEART MUSCLE; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; VASODILATATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CORONARY CIRCULATION; CORONARY VESSELS; CYCLIC AMP; DOGS; FEMALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; RECEPTORS, ATRIAL NATRIURETIC FACTOR; VASODILATION; VASODILATOR AGENTS;

EID: 84905439864     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.70     Document Type: Article

References (39)

1. Jessup M, Brozena S. Heart failure. New Engl J Med 2003; 348: 2007-2018.
2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. New Engl J Med 2002; 347: 1397-1402.
3. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
4. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction-comparison with nonischemic cardiomyopathy. Circ J 2005; 69: 143-149.
5. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 2004; 44: 276-286.
6. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
7. Nakao K, Yasoda A, Ebihara K, Hosoda K, Mukoyama M. Translational research of novel hormones: lessons from animal models and rare human diseases for common human diseases. J Mol Med 2009; 87: 1029-1039.
8. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21: 733-741.
9. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 69: 318-328.
10. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-1493.
11. Booz GW. Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counterregulatory system. Hypertension 2005; 45: 341-346.
12. Hussain MB, Hobbs AJ, MacAllister RJ. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta. Br J Pharmacol 1999; 128: 1082-1088.
13. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol 2003; 139: 1289-1296.
14. Sabrane K, Kruse MN, Gazinski A, Kuhn M. Chronic endothelium-dependent regulation of arterial blood pressure by atrial natriuretic peptide: role of nitric oxide and endothelin-1. Endocrinology 2009; 150: 2382-2387.
15. Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Kosaka H, Inoue M, Hori M, Kamada T. Beneficial effects of inhibition of angiotensin converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995; 92: 950-961.
16. Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of protein kinase-C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. Circulation 1996; 93: 781-791.
17. Green LC, Wagner DA, Glogowski J, Skipper JS, Wishinok SR. Analysis of nitrate, nitrite and [15 N]nitrate in biological fluid. Anal Biochem 1982; 126: 131-138.
18. Honma M, Satoh T, Takezawa J, Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small volume samples from blood and tissue. Biochem Med 1977; 18: 257-273.
19. Lowry Oh, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
20. Mori H, Haruyama S, Shinozaki Y, Okino H, Iida A, Takanashi R, Sakuma I, Husseini WK, Payne BD, Hoffman JI. New nonradioactive microspheres and more sensitive X-ray fluorescence to measure regional blood flow. Am J Physiol 1992; 263: H1946-H1957.
21. Snedecor GW, Cochran WG. Statistical Methods, 6th edn. Iowa State University Press, Ames, IA, 1972, pp 258-298.
22. Winer BJ. Statistical Principles in Experimental Design, 2nd edn. McGraw-Hill, New York, 1982, pp 1-907.
23. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101: 812-818.
24. Kitakaze M, Node K, Minamino T, Kosaka H, Shinozaki Y, Mori H, Inoue M, Hori M, Kamada T. Role of nitric oxide in regulation of coronary blood flow during myocardial ischemia in dogs. J Am Coll Cardiol 1996; 27: 1804-1812.
25. Mtairagel M, Houard X, Rais S, Pasquier C, Oudghiri M, Jacob MP, Meilhac O, Michel JB. Pharmacological potentiation of natriuretic peptide limits polymorphonuclear neutrophil-vascular cell interactions. Arterioscler Thromb Vasc Biol 2002; 22: 1824-1831.
26. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM, Ritchie RH. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 2006; 72: 112-123.
27. Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K, Suzuki S, Mizuno Y, Sugiyama S, Saito Y, Nakao K, Yasue H, Ogawa H. Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 2007; 71: 1040-1046.
28. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelial-derived vascular relaxing factor. Nature 1986; 320: 454-456.
29. Kitakaze M, Hori M, Takashima S, Iwai K, Sato H, Inoue M, Kitabatake A, Kamada T. Superoxide dismutase enhances ischemia-induced reactive hyperemic flow and adenosine release in dogs: a role of 5'-nucleotidase activity. Circ Res 1992; 71: 558-566.
30. Costa MA, Elesgaray R, Loria A, Balaszczuk AM, Arranz C. Atrial natriuretic peptide influence on nitric oxide system in kidney and heart. Regul Pept 2004; 118: 151-157.
31. Costa MA, Elesgaray R, Caniffi C, Fellet A, Mac Laughlin M, Arranz C. Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic peptide in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 298: H778-H786.
32. Calderone A. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart Fail Rev 2003; 8: 55-70.
33. Kim JS, Ohshima S, Pediaditakis P, Lemasters JJ. Nitric oxide: a signaling molecule against mitochondrial permeability transition-and pH-dependent cell death after reperfusion. Free Radic Biol Med 2004; 37: 1943-1950.
34. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006; 101: 311-318.
35. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007; 115: 1895-1903.
36. Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, Ferdinandy P. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol 2010; 105: 643-650.
37. Padilla F, Garcia-Dorado D, Agulló L, Barrabés JA, Inserte J, Escalona N, Meyer M, Mirabet M, Pina P, Soler-Soler J. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001; 51: 592-600.
38. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-1826.
39. Hernandez Adrian F. Acute study of clinical effectiveness of nesiritide in decompensated heart failure. Late Breaking Clinical Trial Session of 2010 AHA.